Literature DB >> 7585585

Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta.

R K Wali1, B P Frawley, S Hartmann, H K Roy, S Khare, B A Scaglione-Sewell, D L Earnest, M D Sitrin, T A Brasitus, M Bissonnette.   

Abstract

Several lines of evidence from our laboratory and others indicate that epigenetic alterations in protein kinase C (PKC) are involved in colonic carcinogenesis in both man and experimental animals. Furthermore, bile salts, known activators of PKC, have also been implicated in colonic tumor development. Recently, however, our laboratory has demonstrated that, whereas dietary cholic acid increased the occurrence of azoxymethane (AOM)-induced rat colonic tumors, ursodeoxycholic acid was associated with a significant protective effect. In the present studies, we therefore examined changes in PKC isoforms that accompanied AOM-induced tumor formation and investigated whether the chemopromotional and/or chemopreventional actions of these supplemental dietary bile salts involved changes in specific isoforms of PKC. Rats treated with vehicle (saline) or AOM and maintained on bile salt unsupplemented or supplemented diets were used to isolate control colonocytes and carcinogen-induced tumors, which were then subjected to subcellular fractionation. The homogenates and subcellular fractions were then probed for individual PKC isoforms by quantitative Western blotting using isoform-specific antibodies. Normal rat colonocytes expressed PKC-alpha, -beta II, -delta, -epilson, and -zeta. AOM, in unsupplemented or cholate-supplemented groups, caused significant down-regulation of PKC-alpha, -delta and -zeta and up-regulation of PKC-beta II, while increasing particulate PKC-alpha, -beta II, and -zeta in carcinogen-induced tumors compared to normal colonocytes. Dietary supplementation with ursodeoxycholic acid, in marked contrast to these groups, prevented the changes in the subcellular distributions of PKC-alpha, -beta II, and -zeta, and preserved the expression of PKC-zeta in AOM-induced tumors. These studies suggest that changes in specific isoforms of PKC (particularly, PKC-alpha, -beta II, -delta, and/or -zeta) are involved in colonic malignant transformation in the AOM model but do not account for the chemopromotional actions of cholic acid in this model. Furthermore, the ability of ursodeoxycholic acid to block AOM-induced increases in particulate PKC-alpha, -beta II, and -zeta, and/or inhibit down-regulation of PKC-zeta, may contribute to the chemopreventive effects of this bile acid.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585585

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Deepak Poudyal; Alexander A Chumanevich; Tia Davis; Anthony Windust; Anne Hofseth; Wensong Wu; Joshua Habiger; Edsel Pena; Patricia Wood; Mitzi Nagarkatti; Prakash S Nagarkatti; Lorne Hofseth
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

2.  In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.

Authors:  Sui Peng; Xiaofang Huo; Davood Rezaei; Qiuyang Zhang; Xi Zhang; Chunhua Yu; Kiyotaka Asanuma; Edaire Cheng; Thai H Pham; David H Wang; Minhu Chen; Rhonda F Souza; Stuart Jon Spechler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-22       Impact factor: 4.052

Review 3.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

4.  High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

Authors:  John E Eaton; Marina G Silveira; Darrell S Pardi; Emmanouil Sinakos; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2011-05-10       Impact factor: 10.864

5.  Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor.

Authors:  Darcey L H Smith; Pavitra Keshavan; Uri Avissar; Kashif Ahmed; Stephen D Zucker
Journal:  Carcinogenesis       Date:  2010-03-01       Impact factor: 4.944

6.  C1B domain peptide of protein kinase Cγ significantly suppresses growth of human colon cancer cells in vitro and in an in vivo mouse xenograft model through induction of cell cycle arrest and apoptosis.

Authors:  Atsushi Kawabata; Takaya Matsuzuka; Chiyo Doi; Garret Seiler; Jennifer Reischman; Lara Pickel; Rie Ayuzawa; Thu A Nguyen; Masaaki Tamura
Journal:  Cancer Biol Ther       Date:  2012-08-01       Impact factor: 4.742

Review 7.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

8.  Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR.

Authors:  Rebecca Feldman; Jesse D Martinez
Journal:  Biochim Biophys Acta       Date:  2009-05-13

Review 9.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

Review 10.  Consequences of bile salt biotransformations by intestinal bacteria.

Authors:  Jason M Ridlon; Spencer C Harris; Shiva Bhowmik; Dae-Joong Kang; Phillip B Hylemon
Journal:  Gut Microbes       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.